IMCY-0141 / Imcyse - LARVOL DELTA

IMCY-MS-001: IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study (clinicaltrials.gov) - P1/2 | N=150 | Active, not recruiting | Sponsor: Imcyse SA | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Multiple Sclerosis • CD4 • CD8

Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of Imotope IMCY-0141 for the Treatment of Multiple Sclerosis (Issuer Direct) - "Imcyse...announced completion of enrollment and initial dosing in the Phase 1 portion of its adaptive Phase 1/2 clinical trial, IMCY-MS-001. The Phase 1 open-label, dose escalation part of the study is assessing the safety of three doses of Imotope™ IMCY-0141 in patients with relapsing-remitting multiple sclerosis (RRMS)....'We expect the final outcome of the IDMC's review of the data from the third and highest dose level from our Phase 1 trial by the end of this year'."

P1 data • Trial status • Multiple Sclerosis

IMCY-MS-001: Study of IMCY-0141 in Recent Onset of Multiple Sclerosis (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Imcyse SA

New P1/2 trial • CNS Disorders • Multiple Sclerosis